[3][5] Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[6] and hence is a TNF inhibitor.

Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism.

Janssen markets golimumab in Canada, Central and South America, the Middle East, Africa and Asia Pacific.

In the European Union, Russia, and Turkey, golimumab distribution rights are held by MSD (Ireland), a subsidiary of Merck & Co., Inc.

[21] Unlike other TNFi treatments such as adalimumab and certolizumab pegol, there have been no reported cases of drug-induced lupus-like syndrome (DILS).